Guillain-Barré syndrome (GBS) is an acute immune-mediated polyradiculoneuropathy with a worldwide incidence of 0.81-1.89 per 100 000 person-years. In Europe and North America only 5% of patients with GBS have axonal subtypes, which in South America and Asia account for 30%-47% of cases. The aim of our study is to assess the annual incidence and clinical features of GBS in La Spezia area in Italy. A retrospective (from 1 January 2003 to 31 December 2011) followed by a prospective (from 1 January 2012 to 31 December 2015) analysis was carried out on patients admitted to La Spezia hospital who fulfilled the GBS diagnostic criteria. A total of 86 patients (58 men), mean age of 62.7 years (range 21-90), were included. The mean annual incidence rate was 3/100 000 (range: 0.9/100 000-5.37/100 000) significantly higher than the European incidence (P < 0.001). Forty-seven percent were classified as acute inflammatory demyelinating polyradiculoneuropathy (AIDP), 35% as acute motor and motor-sensory axonal neuropathy (AMAN-AMSAN), 13% as variant forms, and 5% were not defined. AIDP was most common in "Golfo dei Poeti" (50%) and "Val di Magra" (63.2%), whereas AMAN/AMSAN prevailed in "Val di Vara" (63.6%) and "Riviera Spezzina" (62.5%) (P = 0.024). In La Spezia area GBS incidence (especially the AMAN subtype) is significantly higher than the incidence reported in Europe. AIDP predominates in the eastern area whereas AMAN/AMSAN in the western, with a significantly different incidence rate (P = 0.003). Prospective studies to assess possible predisposing environmental factors are needed. person-years, with an age-related increasing risk and male predominance (men/women 3:2).
2 GBS incidence shows geographical variability, from the lowest rate in Finland (0.38/100 000/year), 3 to the highest in Curaçao (253/100 000/year). 4 In Europe and North America annual incidence rates are 0.84-1.91/100 000. 5 According to the recent ITANG study, 6 in Italy the annual incidence rate is 1.84 per 100 000, among the highest in western countries, although only a minority of Italian regions was involved in the study. There is not a worldwide consensus on the seasonality of GBS, as higher rates seem to occur in winter in colder regions and in spring in temperate areas. 7 In Italy GBS peaks in January and February, possibly related to viral infections and vaccinations. 6 GBS may present in two main forms: acute inflammatory demyelinating polyradiculoneuropathy (AIDP) that accounts for the majority of cases in western countries, and acute motor and motor-sensory axonal neuropathy (AMAN-AMSAN) more frequent in South America and Asia (30%-65% of cases) than in western countries (5%-10% 3 | RESULTS
| Epidemiology and anamnestic data
A total of 92 GBS patients were admitted to the Neurology Unit of 
| Clinical and electrophysiological features
Clinical and electrophysiological characteristics of the cohort are reported in Table 1 Two electrophysiological studies were available in 40 patients:
one at 1-7 days from the GBS onset and the second after 20-30 days.
A single electrophysiological study was performed in 35 patients who were hospitalized after at least 15 days from symptoms onset. The classification based on the first and on the second study is shown in Table 2 .
Patients coming from western areas had a higher risk of developing axonal GBS (OR = 4.80), more significant at multivariate analysis AIDP, acute inflammatory demyelinating polyradiculoneuropathy; AMAN, acute motor axonal neuropathy; AMSAN, acute motor sensory axonal neuropathy; CSF, cerebrospinal fluid; EGRIS, Erasmus GBS respiratory insufficiency score; GBS, Guillain-Barré syndrome; GBS-DS, GBS-Disability Scale; IQR, interquartile range; mEGOS, modified Erasmus GBS outcome score; MRC scale, Medical Research Council scale. a Considering the first electrophysiological study in the 40 patients who performed two studies. b Considering the second electrophysiological study in the 40 patients who performed two studies. c An electrophysiological study was performed in 40 patients at 1-7 days and after 20-30 days from the onset. A single electrophysiological study was performed in 35 patients who were hospitalized after at least 15 days from disease onset.
FIGURE 1
Annual Guillain-Barré syndrome (GBS) incidence rate per year. The mean annual incidence rate was 3/100 000 person-year, significantly higher than European incidence Demyelinating forms were significantly more frequent in Golfo dei Poeti (50%) and Val di Magra (63.2%) areas, whereas axonal forms were more frequent in Val di Vara (63.6%) and Riviera Spezzina (62.5%) (P = 0.024). Thus AIDP was mainly found in eastern areas, while AMAN/AMSAN were more represented in western areas (P = 0.003) (Figure 3 ).
| Serological and CSF analysis
Only 60 % of patients had hospital biochemical examinations CSF data were available from 65 samples: 58 showed albuminocytological dissociation, 27 with CSF protein ≥1 g/dL.
| Treatment
All the patients were treated, except for one who suddenly died after admission for respiratory failure. Forty-four (51%) patients were treated with IVIg and 20 (23.26%) with PEX. Twenty-one (24.41%) patients received combined therapy. Forty (52.32%) patients were treated within 7 days from the clinical onset.
| Prognosis and outcome
Five patients died of respiratory failure, 1 soon after hospital admission. After discharge, 61 patients needed rehabilitation program. MRC sumscore, GBS-DS, mEGOS and EGRIS values at admission are reported in Table 1 . Among the 59 patients whose data were available at 6-months follow up, 18 (30.5%) were unable to walk independently, 61.1% with mEGOS ≥7 at hospital admission. mEGOS at baseline and GBS-DS were strongly correlated at T1 (P < 0.001) and T6 (P < 0.009).
Although GBS-DS score in AMAN was higher at T0 and remained higher during follow up as compared to AIDP (3.24 vs 2.56 at T1; 2.14 vs 1.81 at T6), no-significant differences were detected between AMAN and AIDP at T1 and at T6, showing similar outcome.
Among the 21 patients who developed respiratory insufficiency, 71.4% had EGRIS ≥6 at hospital admission. EGRIS strongly correlated with respiratory failure (P < 0.001) and with GSB-DS at 1 and 6 months follow up (P < 0.001). Multivariate analysis indicated respiratory insufficiency as the only variable independently predictive of disability. Also autonomic dysfunction and delayed (> 7 days) therapy correlated with disability outcome at T1 (P < 0.015).
| DISCUSSION
The results of our study show that the mean annual incidence of GBS in La Spezia area (3/100 000/year) is significantly higher than the incidence reported not only in Italy ( 6,21 ; [22] [23] [24] ) and in Europe 2 ( Figure 1) but also in the Caribbean Island of Curaçao. 4 Moreover, although the demyelinating GBS was the most common (47%), the occurrence of axonal forms (35%), was surprisingly higher than that reported in western countries, and similar to Asian, South American and Central American areas. 10, 25 Axonal forms seem to be more common in Southern than in 
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GBS following primary CMV infection is usually characterized by sensory deficits and summer periodicity. 32 Also our three CMV-GBS were hospitalized in summer but contrary to what previously reported, were all AMAN.
We also noted a significant cluster in spring months as reported in temperate areas 7 but discordant from what previously reported in Italy. 6 Despite treatment, 5% of the patients died, percentage in line with previous reports, 33 while 30.5% were unable to walk independently at 6 months, exceeding previously reported rate of 20%. 34 Classically AMAN is considered related to poorer prognosis than AIDP. We instead found a similar disability pattern at 6-months in axonal and demyelinating GBS, although the first seemed to be more severe at onset. Moreover, we did not find difference in respiratory distress in AIDP and AMAN.
Our study confirms the reliability of mEGOS and EGRIS prognostic scales, as we found a significant correlation between mEGOS at baseline and GBS-DS at follow up and between EGRIS and the occurrence of respiratory insufficiency that was linked to disability prognosis at T1 and T6.
Autonomic dysfunction is described in 66.7% of GBS patients. 35 In our study it was present in 23% of patients. As autonomic dysfunction is less present in axonal GBS, 35 the frequency of AMAN in our cohort may account for the low rate of autonomic dysfunctions.
In conclusion, we have shown that in La Spezia area GBS incidence-especially the AMAN subtype-outweighs the incidence usually reported in Europe. AIDP predominates in the eastern zone and AMAN/AMSAN in the western zone of La Spezia area. Prospective studies to assess possible relationships to environmental factors are needed.
